Stay updated on Eli Lilly and Company Press Releases
Sign up to get notified when there's something new on the Eli Lilly and Company Press Releases page.

Latest updates to the Eli Lilly and Company Press Releases page
- Check5 days agoChange DetectedThe press releases list has been updated with several new headlines and dates highlighting recent company news and research, while older items such as conference participation and community initiatives have been removed. This update refreshes the page content to reflect current news and priorities.SummaryDifference8%

- Check12 days agoChange DetectedThe press releases page was updated with multiple new entries, including conference participation, three acquisitions in infectious disease, trial updates on VERVE-102 and Foundayo, oncology portfolio showcasing at ASCO, and other corporate news. Older items such as anniversary campaign commitments, dividend declarations, and manufacturing expansion announcements were removed.SummaryDifference9%

- Check19 days agoChange DetectedThree new press releases were added to the page, announcing conference participation, a community sports initiative, and UNICEF collaboration, each with their datelines; at the same time, three items were removed, including the Kelonia Therapeutics acquisition, the Q1 2026 earnings conference date, and ACHIEVE-4 safety updates.SummaryDifference8%

- Check27 days agoChange DetectedAdds new entries about weight-loss trial results for Foundayo and lower-dose Zepbound, and announces Lilly's philanthropic initiative tied to its 150th anniversary. It also removes several older entries from the listing, narrowing the feed to more recent announcements.SummaryDifference8%

- Check34 days agoChange DetectedNew press releases and corporate updates have been added to the Lilly press releases page, including Omvoh UC disease clearance data, a Q1 2026 financial update, a second-quarter dividend declaration, and several acquisitions. Older items, such as Foundayo pricing details and Centessa acquisition content, have been removed.SummaryDifference8%

- Check41 days agoChange DetectedNew addition: Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera, including AJ1-11095 details. Deletion: removal of the press release detailing Taltz plus Zepbound efficacy in psoriatic arthritis and obesity.SummaryDifference2%

Stay in the know with updates to Eli Lilly and Company Press Releases
Enter your email address, and we'll notify you when there's something new on the Eli Lilly and Company Press Releases page.